What is the current stock price of HeartSciences Inc. (HSCS)?

As of the latest market data, HeartSciences Inc. (HSCS) is trading at $2.08. The stock has seen a loss of -3.70% today.

Does HeartSciences Inc. (HSCS) pay a dividend?

Based on current data, HeartSciences Inc. does not have a confirmed active dividend policy.

What is the market cap of HeartSciences Inc.?

The current market capitalization of HeartSciences Inc. (HSCS) is approximately unavailable.

HSCS

HeartSciences Inc.·Healthcare

2.08

3.704%(−0.08)

Market Closed

2.55

22.596%(+0.47)

After Hours

Last Updated: — ET

52W L: $2.0152W H: $6.47

HSCS NEWS

defenseworld.net

1d ago

Comparing 10x Genomics (NASDAQ:TXG) and HeartSciences (NASDAQ:HSCS)

10x Genomics (NASDAQ: TXG - Get Free Report) and HeartSciences (NASDAQ: HSCS - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation. Institutional and Insider Ownership 84.7% of 10x Genomics shares

defenseworld.net

Mar 26

Hinge Health (NYSE:HNGE) versus HeartSciences (NASDAQ:HSCS) Financial Analysis

HeartSciences (NASDAQ: HSCS - Get Free Report) and Hinge Health (NYSE: HNGE - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Valuation and Earnings This table compares HeartSciences and Hinge

globenewswire.com

Mar 25

HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category.

globenewswire.com

Mar 24

HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings

Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET.

globenewswire.com

Mar 16

HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.

globenewswire.com

Feb 5

University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center

Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the University of the West of England (“UWE”) has adopted the Company's MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology.

Company Profile

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

2022-06-16

Beta

2.45

Websiteheartsciences.com↗